Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Capital Employed (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Capital Employed for 11 consecutive years, with 0.65% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 40.0% to 0.65% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.65%, a 40.0% increase, with the full-year FY2024 number at 0.89%, up 8.0% from a year prior.
  • Return on Capital Employed was 0.65% for Q3 2025 at ImmunityBio, up from 0.94% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 2.45% in Q4 2022 to a low of 2.19% in Q2 2021.
  • A 5-year average of 0.59% and a median of 1.0% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: crashed -334bps in 2023, then soared 40bps in 2025.
  • ImmunityBio's Return on Capital Employed stood at 2.19% in 2021, then surged by 212bps to 2.45% in 2022, then crashed by -136bps to 0.88% in 2023, then dropped by -22bps to 1.08% in 2024, then surged by 40bps to 0.65% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Return on Capital Employed are 0.65% (Q3 2025), 0.94% (Q2 2025), and 1.07% (Q1 2025).